News & Articles

Combining image analysis with structured reporting, the software aims to improve and accelerate the detection of the virus

Avacta and Liverpool School of Tropical Medicine collaborate to clinically validate saliva-based rapid coronavirus test being developed with Cytiva

Test delivers results in just 15 minutes with no instrumentation, using proven lateral flow technology with demonstrated sensitivity of 97.1% and specificity of 98.5%

First participants dosed in trial of AZD7442 to assess safety, tolerability and pharmacokinetics of the combination

Workflow is quick, simple and scalable for high-throughput antibody detection with high PPA sensitivity and NPA specificity

The real-time PCR workflow has a capacity of up to 6,000 tests per day per system, and demonstrated 100% agreement with authorized nasopharyngeal assays

Hear how one trailblazing lab at the Broad Institute of MIT and Harvard is using automated sample tracking to monitor pandemics such as Ebola Virus Disease and COVID-19

The overall goal is to continue to detect and discover critical components in the overall cellular response to COVID-19

QIAseq SARS-CoV-2 Primer Panel converts viral RNA samples into libraries ready for sequencing, whereas QIAGEN Digital Insights solutions support COVID-19 drug, vaccine and epidemiology research

Syndromic testing will streamline respiratory infection diagnosis as COVID-19 pandemic collides with start of flu season

Access Anti-SARS-CoV-2 is an easy-to-use 10-minute test on a portable device that provides highly accurate results on total Ig antibodies

Across all populations, BNT162b2 administration was well tolerated with mild to moderate fever in fewer than 20% of the participants

The test outperforms other molecular tests with a low detection limit of 15 GEC/reaction (250 GEC/ml of sample) and a robust control system

The consortium aims to determine the dynamics, function and potential for therapeutic intervention of the RNA and protein structures of SARS-CoV-2

IgM assay has 95.51% positive predictive value even when disease incidence is only 3%

The new assays are designed to enable turnaround times for next-generation sequencing results of less than 24 hours

Used to empower clinicians to quickly prescribe treatment regimens for multidrug-resistant TB, the test could help fill a critical gap that is jeopardizing global TB targets

Enables labs to quickly ramp up testing capacity and generate results faster

Learn about the potential of lateral flow assays in detecting symptomatic and asymptomatic COVID-19 infections

Dr. Jeremy Hirota takes us through the technology behind his translational research program for respiratory health

Nirsevimab is the first potential passive immunisation for infants to demonstrate sustained protection across the entire RSV season with a single dose